Singapore Reacts to Pfizer’s New Oral Covid‑19 Pill: “Sounds Promising”
The National Centre for Infectious Diseases (NCID) has tossed a friendly green flag, saying Pfizer’s latest antiviral, Paxlovid, looks promising – but they’re holding out for more data before waving it into the local treatment box.
What the Numbers Say
- In a preliminary study, Paxlovid slashed hospitalisation or death chances by 89 % for adults at high risk of severe Covid‑19.
- Targets folks who had mild‑to‑moderate symptoms within five days and are at risk because of chronic lung disease, high blood pressure, or diabetes.
- Pfizer is rushing to file its interim results for U.S. emergency‑use approval, with the rest of the world on a “time‑table not yet disclosed” horizon.
How It Works
Paxlovid packages a new inhibitor with the older anti‑viral ritonavir, which slows the pill’s breakdown so it lingers longer in the body. The combo hits the 3CL protease – an enzyme that virus needs to copy itself. Because the enzyme’s shape stays pretty much the same across coronavirus strains, Pfizer believes variants won’t dent the pill’s effectiveness.
The Bigger Picture – A Quick Look at Competing Therapies
- Molnupiravir (Merck & Ridgeback) – halves hospitalisation/death risk in high‑risk patients.
- Older stand‑outs: dexamethasone (steroid), remdesivir, antibody cocktails like sotrovimab and tocilizumab, and anti‑inflammatory baricitinib.
- There’s talk about fluvoxamine (an antidepressant) cutting the inflammatory cascade, but evidence remains flakey.
Fluvoxamine – A Quick Critique
Dr Shawn Vasoo of NCID points out:
- Brazil study showed no clear difference in viral clearance, hospitalisation, or death.
- St. Louis trial was small and only followed patients for 15 days – far too short to shout “miracle!”
- Endpoints like “spending >6 hrs in ED” feel too “soft” compared to hard outcomes like death or a 28‑day hospitalisation.
Bottom Line
It’s a bustling era of oral antivirals. Paxlovid’s 89 % drop in severe outcomes is a strong headline, but until the full dossier is under review by Singapore’s Health Sciences Authority, we’ll stay on the sidelines and watch the next chapter unfold.
